Assyro AI

FDA Orange Book · active-ingredient family

Dimethyl fumarate

Dimethyl fumarate is approved as 1 brand and 17 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:TECFIDERA · NDA 204063

1

Brand (NDA)

17

Generics (ANDA)

9

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, delayed release

ProductApplicantApplicationTEApproved
TECFIDERARLD×2BIOGENNDA 204063ABMar 27, 2013

Generic (ANDA) products (17)

ProductApplicantApplicationTEApproved
DIMETHYL FUMARATE×2TORRENTANDA 210390Jan 06, 2025
DIMETHYL FUMARATE×2MACLEODS PHARMS LTDANDA 210377ABJun 26, 2024
DIMETHYL FUMARATE×2AUROBINDO PHARMAANDA 210385ABDec 22, 2022
DIMETHYL FUMARATE×2PRINSTON INCANDA 210414ABOct 18, 2022
DIMETHYL FUMARATE×2SAWAI USAANDA 210285Dec 21, 2021
DIMETHYL FUMARATE×2SOLA PHARMSANDA 210436ABMar 26, 2021
DIMETHYL FUMARATE×2TWI PHARMSANDA 210382ABOct 14, 2020
DIMETHYL FUMARATE×2GLENMARK PHARMS LTDANDA 210309ABOct 06, 2020
DIMETHYL FUMARATE×2LUPINANDA 210226ABOct 05, 2020
DIMETHYL FUMARATE×2ACCORD HLTHCAREANDA 210499ABSep 24, 2020
DIMETHYL FUMARATE×2ALKEM LABS LTDANDA 210440ABSep 24, 2020
DIMETHYL FUMARATE×2AMNEALANDA 210402ABSep 24, 2020
DIMETHYL FUMARATE×2CIPLAANDA 210305Sep 24, 2020
DIMETHYL FUMARATE×2HETERO LABS LTD IIIANDA 210500ABSep 24, 2020
DIMETHYL FUMARATE×2MSNANDA 210460ABSep 24, 2020
DIMETHYL FUMARATE×2ZYDUS PHARMSANDA 210538Sep 24, 2020
DIMETHYL FUMARATE×2MYLANANDA 210531Aug 17, 2020

Listed patents (9)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8399514Feb 07, 2028in 1 yr 8 mo
U-1384
10391160Mar 13, 2035in 8 yr 10 mo
U-3148
10555993Mar 13, 2035in 8 yr 10 mo
U-3148
10994003Mar 13, 2035in 8 yr 10 mo
U-3148
10959972Nov 16, 2035in 9 yr 7 mo
U-1384
11129806Nov 16, 2035in 9 yr 7 mo
U-1384
11007166Nov 16, 2035in 9 yr 7 mo
U-1384
11007167Nov 16, 2035in 9 yr 7 mo
U-1384
11246850Nov 16, 2035in 9 yr 7 mo
U-1384

Dimethyl fumarate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.